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BACKGROUND: The management of refractory glaucoma is a challenging task for any glaucoma 
surgeon. This study is aimed to evaluate the efficacy of Ahmed Glaucoma Valve implantation in 
refractory glaucomas in South-West Ethiopia. 
METHODS: A retrospective review was conducted on the charts of consecutive patients treated with 
Ahmed glaucoma valve implantation at Jimma University Specialized Hospital between August 2012 and 
August 2014. Success was defined as Intraocular Pressure (IOP) less than 22 mm Hg and greater than 
5mm Hg at 6 months, with at least 30% reduction from baseline, without medical therapy (complete 
success) or either with or without medication (qualified successes).. 
RESULTS: A total of 12 eyes of 11 patients were included. The mean age of patients was 40.7 (SD= 19.0) 
years; 63.6% of them were males. The main types of glaucoma were pseudoexfoliative (3 eyes), uveitic (2 
eyes), chronic angle closure (2 eyes) and Juvenile Open Angle (JOAG) (2 eyes). The mean IOP was 
reduced from preoperative level (32.75±7.14 mmHg) to (15.75 ±4.35 mmHg) at six postoperative  months, 
(P<0.001); 66.7% eyes had complete successes while 83.3% had qualified success. Intra- operative 
complications were encountered in 2(16.7%) eyes, while 5/12 (41.7%) eyes had post-operative 
complications-hypotony (one with choroidal effusion) and progression of cataract in 2 eyes each. 
Hypertensive phase was diagnosed in 2(16.7%) eyes. 
CONCLUSION: The Ahmed glaucoma valve implant appears to be effective and relatively safe for 
treating complicated glaucomas with success rate comparable with those reported from other studies.  
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INTRODUCTION  
Africa is a region with the highest prevalence of 
glaucoma (1, 2), and most patients present with 
advanced stage of the disease or unilateral 
blindness with high intraocular pressure (IOP) (3).  
Glaucoma filtration procedures (Trabeculectomy) 
are commonly required for IOP control and 
preservation of vision. The African race is also 
associated with higher rate of failure of 
trabeculectomy (4). It is always a challenge for 
ophthalmologists in the region in dealing with 
such failed cases of trabeculectomy and other 
complex secondary glaucomas. 
Glaucoma drainage devices (GDD) are 
generally used for such refractory cases where  
conventional surgery has failed or is likely to fail; 
these also include uveitic glaucoma, neovascular 
glaucoma, previous ocular surgery or other 
conditions associated with conjunctival scarring. 
The plates of glaucoma implants offer a large 
surface area reservoir for the drainage of aqueous 
humor and prevent excessive scar tissue formation 
at the limbus (5). 
GDD include the open tube drainage devices like 
Molteno implant, the Baerveldt implant and the 
Schocket tube shunt, and the flow-restrictive 
drainage devices like the Krupin and the Ahmed 
Glaucoma Valve (AGV) implants (6). Restrictive 
devices contain a valve that is designed to reduce 
the incidence of postoperative hypotony, while 
offering the benefit of immediate pressure 
reduction. The AGV is being widely used 
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There is a scarcity of data on the outcome of GDD 
surgery in Africa. Studying the outcomes of these 
types of surgeries is important as a quality control 
and to compare results with experience in other 
areas. It will also serve as a baseline for future 
interventions.  In a retrospective case series 
investigating, the outcomes of AGV among 25 eyes 
of children and adult patients in Kenya, Kiage et al 
reported 79% success and 53.3% mean IOP 
reduction at 2 a months’ follow-up (8). A recent 
retrospective review of 13 eyes of 12 patients who 
underwent this surgery in Central Ethiopia showed 
a success rate of IOP controlling of 76.9% (9). The 
current study was carried out to describe the initial 
experience of AGV implant surgery in a tertiary 
hospital in Southwest Ethiopia.  
 
PATIENTS AND METHODS 
 
This is a retrospective review of the medical 
records of patients with refractory glaucoma who 
underwent isolated tube shunt surgery using AGV 
in the Department of Ophthalmology, Jimma 
University Specialized Hospital, between August 
2012 and August 2014. Patients who had 
completed postoperative follow-up of 6 months and 
for whom IOP was taken at baseline and during the 
follow-up period were included. All eyes had 
glaucoma, which could not be controlled by 
medications and/or previous glaucoma surgery. The 
diagnosis of glaucoma was based on the IOP, 
characteristic optic nerve pathology with or without 
visual field changes.  
A predesigned format was used to retrieve 
clinical information from the charts which included 
age and sex of the patients, type of glaucoma, 
previous ocular surgery, current surgical procedure 
and pre- and post-operative visual acuity (VA), IOP 
and glaucoma medications. IOP was measured 
using Goldman applanation tonometer mounted on 
slit lamp or iCare rebound tonometer (iCare 
Finland, Helsinki, Finland). Postoperative IOP 
taken at 1
st







postoperative periods were included. Any 
intraoperative and postoperative complication was 
also noted.  The clinical data was collected by a 
senior ophthalmology resident in the department 
and the author; all surgical procedures were 
performed by the same surgeon (GG).  
Surgical method: General steps followed in the 
procedure are described elsewhere (6). In this 
series, AGV consisting of a silicone tube connected 
to a silicone reservoir plate (FP7 or FP8 models) 
[New World Medical Inc., Rancho Cucamonga, 
California] was used (6). Model FP7 with large 
surface area of 184 mm
2
 was inserted in 11 eyes 
and model FP8 with surface area of 96mm
2 
in 1 
eye. Surgery was performed using retro‑ bulbar or 
sub‑ tenon anesthesia. AGV was implanted in the 
upper temporal fornix in all cases, 9-0 nylon was 
used to suture the implant to the sclera, and either 
human sclera or cornea was used to cover the tube 
near the limbus.  
Definition of success and failure: The primary 
outcome variable for success was postoperative 
IOP control in 6 months, i.e. IOP less than 
22mmHg and more than 5mmHg with at least 30% 
reduction from the preoperative level in the absence 
of devastating ocular complications.  Eyes that met 
the above criteria and were not on supplemental 
anti-glaucoma medical therapy were defined as 
complete successes and those that met the criteria 
either with or without supplemental medical 
therapy were defined as qualified successes. 
Hypotony was defined as IOP less than or equal to 
5mm Hg on any post-operative visit. Hypertensive 
phase (HP) was defined as an IOP measurement of 
greater than 21mmHg (with or without 
medications) during the 6-month postoperative 
period that was not a result of tube obstruction, 
retraction or malfunction. Resolution of this phase 
was IOP of less than 22mmHg along with a 
reduction of the IOP by 3mmHg or more with the 
same or less number of medications (10). Cataract 
was considered to have progressed if there was loss 
of 2 lines of Snellen VA that was attributed to 
cataract at the six-month follow-up visit. 
Clinical data was analyzed using SPSS 
software for Windows Version 16 (IBM Corp., 
New York, NY, USA). Simple descriptive statistics 
(frequency, mean, percentage) were used to 
describe the study variables. The difference of the 
mean postoperative IOP was compared from 
baseline level using student’s t-test. Due to the 
sample size,advanced statistical methods are not 
used to look for possible factors associated with 
success and failure of the procedure.  
Ethical clearance: The study was done with 
adherence to the guidelines of the Declaration of 
Helsinki. Ethical clearance was obtained from the 
Department of Ophthalmology, College of Public 
Health and Medical Sciences, Jimma University. 
As part of our routine practice, patients provided 
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written consent preoperatively after the purpose of 
the surgery, expected outcomes, possible 
complications and postoperative care had been 
explained to them. Clinical data were retrieved with 




A total of 19 eyes of 18 patients underwent AGV 
implant surgery during the specified period. Two 
patients (2 eyes) who did not have follow-up 
beyond the first postoperative month and 2 children 
(3 eyes) (less than 4 years of age) were excluded. 
Two charts could notbe retrieved. Therefore, data 
of 12 eyes of 11 patients were included in this 
study. 
The mean age of patients was 40.7 (SD = 
19.0) years (range = 12-67 years); 63.6% were 
males. The most common diagnosis was 
pseudoexfoliative glaucoma (3 eyes) followed by 
uveitic glaucoma, Juvenile Open Angle Glaucoma 
(JOAG) and chronic angle closure glaucoma (2 
eyes each).  Primary Open Angle Glaucoma 
(POAG), traumatic and silicone oil induced 
glaucoma were diagnosed in 1 eye each. About 
75% of eyes had advanced glaucoma with vertical 
cup-disc ratio of 0.85 and above; and 83% of eyes 
had one or more intraocular surgery or laser 
treatment performed before the current implant, the 
average being 1.58 per eye (see table 1). The types 
of glaucoma medication used included: Timolol 
0.5%, Pilocarpine 4%, Latanoprost 0.005% 
(Xalatan), Bimatoprost 0.03% (Lumigan) and oral 
Acetazolamide. 
The mean (SD) preoperative IOP was 
32.75(7.14) mmHg, the mean IOP at 6 month was 
15.75 (4.35) mmHg, with 51.9% reduction from 
baseline. This was statistically significant 
(P<0.001). The mean postoperative IOP was lower 
than the baseline level for all individual 
postoperative periods; 9.36(4.41), 15.58(7.18), 
16.36(4.78) and 15.75(4.35) at first the week, first, 
second and 6
th
 months respectively (see Fig 1 and 
table 2). According to the study definition, 8/12 
eyes (66.7%) had complete success while 10/12 
eyes (83.3%) had qualified success at 6 month. The 
mean number of medications was reduced from 2.1 
preoperatively to 0.33 at 6 month, with the use of 
acetazolamide tablets reduced from 72.7% to 0.   
 
Table 1: Characteristics of patients treated with Ahmed glaucoma valve implant surgery, Department of 













1 65 M OD 6/18 30 POAG Trabeculectomy 
2 23 M OS 3/60 28 JOAG Trabeculectomy 
3 12 M OS 6/36 38 Traumatic SICS PC IOL; LPI 
4 35 M OS 3/60 31 JOAG 
Trabeculectomy  (twice);  
needling MMC 
5 55 F OD 6/9 23 PXG DLT;  SICS PC IOL 
6 67 M OS 3/60 28 PXG SICS PC IOL 
7 35 F OS 1/60 36 CACG Trabeculectomy; needling 
8 60 M OS 6/18 26 PXG 
Trabeculectomy  MMC; 
needling; DLT 
9 43 M OS 2/60 33 
Silicone oil 
induced 
PPV, Endolaser, Silicone oil; 
SICS PC IOL 
10 35 F OS HM 32 CACG Trabeculectomy; needling 
    11 18 F OD 6/36 38 Uveitic None 
                OS 6/36 50 Uveitic None 
IOP: Intraocular Pressure; POAG: Primary open angle glaucoma; PXG: Pseudoexfoliative glaucoma; CACG: Chronic Angle Closure Glaucoma; 
JOAG: Juvenile Open Angle Glaucoma; SICS PC IOL: Manual small incision cataract surgery with posterior chamber lens; MMC: Mitomycin C; 










Intra-operative complications were encountered in 
2(16.7%) eyes:  conjunctival button hole that 
required suturing and leakage of Silicone oil into 
the anterior chamber in another post-vitrectomized 
eye. A total of 7 post-operative complications were 
recorded in 5(41.7%) eyes; hypotony occurred in 
2(16.7%) eyes, one with choroidal effusion that 
resolved spontaneously. Two eyes (16.7%) had 
progression of cataract; one of them also had tube 
iris touch. Partial tube obstruction occurred in one 
eye (see table 2). Hypertensive phase was 
diagnosed in 2 eyes at first and third post-operative 
months; both had resolution of this phase with 
glaucoma medication.  
VA remained the same or within one line in 7 
(58.3%) eyes while worsened by two lines or more 
in 2(16.7%) eyes, and improved by two lines in 
3(25.0%) eyes.  
 
Table 2: Postoperative clinical profile of patients treated with Ahmed glaucoma valve implant surgery, 









Week 1 Month 1 Month2 Month 6 
1 9 10 12 10 6/36 Tube iris touch; Progression of 
cataract 
2 13 17 21 14 3/60  
3 3 9 7 15 6/18 Hypotony and Choroidal effusion 
4 _ 18 10 20 6/24  
5 4 15 14 19 6/9 Hypotony 
6 12 16 15 18 4/60  
7 10 10 _ 12 1/60  
8 10 15 19 11 6/36 Progression of cataract 
9 18 17 17 22 2/60 Partial tube obstruction 
10 12 10 12 10 1/60   
11.OD 6 14 14 17 6/24  
OS 6 36 17 21 6/24  
 
 
Figure 1: Pre-operative and postoperative 
mean intraocular pressure ; IOP: Intraocular 





The probability of success of AGV implant 
surgeries reported in the literature varies due to 
differences in definition of success rate, in the 
follow-up period, the surgical technique, the type  
of implant used and the study population 
(particularly the glaucoma types).  
In the present study, the mean IOP was 
reduced by 51.9% from the baseline of 32.75 
±7.14 to 15.75 ± 4.35 at 6 month; 8/12 eyes 
(66.7%) had complete successes while 10/12 eyes 
(83.3%) had qualified success. This is in 
agreement with outcomes reported in the 
literature. A success rate of 76.9% at 6 month was 
reported in another study from Ethiopia (9),while 
a 79% success in a 2 months’ follow-up has been 
reported among patients from Kenya 
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(using iCare and Goldman applanation tonometers) 
(8). A cumulative probability of success ranging 
from 66% - 94% at 12 month has also been 
reported from Asia and other regions of the world 
(5, 11-14).  
The efficacy of a glaucoma surgery in 
reducing IOP must be interpreted in the context of 
its adverse events, with evaluation of the incidence 
and severity of associated complications (15). In 
our series, intraoperative and postoperative 
complications were encountered in 2/12(16.7%) 
and 5/12(41.7%) eyes respectively; acceleration of 
cataract, hypotony, choroidal effusion and tube iris 
touch are among the commonly reported 
postoperative complications.  No major 
complications related with tube (erosion, exposure, 
corneal touch) or devastating ocular complications, 
requiring secondary intervention, were also 
encountered. The visual deterioration observed in 
two eyes was explained by the progression of 
cataract. The overall intraoperative complication 
rate reported from the Ahmed Baerveldt 
Comparison (ABC) study was 10% (16). In the 
Ahmed Versus Baerveldt study (17) and the ABC 
Study, 45% and 43% of patients in the AGV 
arm/group experienced postoperative 
complications respectively. Complications 
reported in these studies were similar to those we 
encountered in our series. Three eyes had 
improvement of two lines or more of VA, and this 
is explained by clearing of corneal edema 
postoperatively in all cases.  
Following GDD surgeries, a hypertensive 
phase (HP) can develop between 4 and 16 weeks 
postoperatively, during which IOP may rise into 
the high 20s or 30s (10).
 
HP was diagnosed in 
2/12(16.6%) of our series, at the 1
st
 and third 
months postoperatively. This is similar to a 
reported prevalence of 15.8% and 18.4% of 





respectively (18), while it has been identified in up 
to 63.2% of patients (10, 19). On the other hand, 
some studies did not find this hypertensive phase 
(5), including series of patients with uveitic 
glaucoma (12). The AGV is said to be associated 
with a higher incidence of the HP, which peaked at 
the 1
st
 month and stabilized by 6 months after the 
operation (20-21). This course goes in line with 
our experience.  
It has been hypothesized that the implant 
type, material and surface area may affect the 
degree of IOP reduction, with a small retrospective 
comparison suggesting that the FP7model lower 
IOP more than the S2 model does (22), and a 
review of implants shows that large end plates 
achieve greater pressure reduction (23). While we 
used implants with silicone tubes and plates for all 
of our patients and the only eye that received the 
small surface area FP8 model in our series is in the 
failure group,  it is difficult to compare this with 
other studies or between groups due to small 
number of eyes studied. 
The major limitation of this study is the small 
sample size and the short period of follow-up. 
Post-operative follow-up as well as follow-ups to 
prescribed medications are well-recognized 
problems in most parts of Africa (24). It can also 
be said that in such cases where patient follow-up 
and compliance is a concern, the AGV may have 
been wiser options to preserve vision due to a 
lesser rate of early post-operative complications 
and need for post-operative interventions (25).  
Despite these, we hope that this study reflects one 
arm of African experience on this novel surgical 
intervention.  
In conclusion, Ahmed Glaucoma Valve 
implantation appears to be a safe and effective 
modality of treatment for complicated glaucoma in 
Ethiopians with an overall success at early stages 
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